Business Context and Reporting Period
Company: AnaptysBio, Inc. (ANAB)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2024
Business Overview: AnaptysBio is a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. Its pipeline includes rosnilimab (PD-1 agonist) and ANB032 (BTLA agonist) in Phase 2 trials. The company generates revenue primarily through collaboration agreements and royalty monetization, notably with GlaxoSmithKline (GSK) regarding the immuno-oncology drug Jemperli.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Collaboration Revenue | $30,017 | $3,318 | $48,167 | $8,152 |
| Total Operating Expenses | $52,774 | $41,050 | $153,446 | $130,428 |
| Net Loss | $(32,851) | $(37,308) | $(123,447) | $(121,408) |
| Diluted Net Loss Per Share | $(1.14) | $(1.41) | $(4.46) | $(4.49) |
| Cash, Cash Equivalents & Investments | $458.0 million (as of Sept 30, 2024) | |||
| Liability for Sale of Future Royalties | $350.6 million (as of Sept 30, 2024) |
Liquidity: As of September 30, 2024, the company held $191.6 million in cash and cash equivalents and $266.5 million in short-term and long-term investments. Management believes current resources are sufficient to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Surge: Collaboration revenue increased significantly to $30.0 million in Q3 2024 from $3.3 million in Q3 2023. This was driven by a $15.0 million sales milestone recognized when GSK's Jemperli annual sales exceeded $250 million, plus increased royalty revenue.
- Expense Growth: Operating expenses rose to $52.8 million in Q3 2024 from $41.1 million in Q3 2023. Research and Development (R&D) expenses increased by $11.3 million, primarily due to higher clinical expenses ($8.8 million increase) and salaries/stock-based compensation ($4.9 million increase).
- Non-Cash Interest Expense: Non-cash interest expense related to the sale of future royalties increased to $15.4 million in Q3 2024 from $4.4 million in Q3 2023. This increase is attributed to the May 2024 amendment of the Jemperli Royalty Monetization Agreement, which increased the threshold amounts payable to the investor (Sagard).
- Financing Activity: In August 2024, the company completed a public offering of 2.75 million shares, raising net proceeds of approximately $93.9 million. Additionally, the company received $50.0 million from an amendment to the Jemperli Royalty Monetization Agreement.
Guidance, Outlook, and Risks
Outlook and Milestones:
- Rosnilimab (RA): Top-line data from the Phase 2b trial in rheumatoid arthritis is expected in February 2025.
- Rosnilimab (UC): Top-line data from the Phase 2 trial in ulcerative colitis is expected in Q1 2026.
- ANB032 (AD): Top-line data from the Phase 2b trial in atopic dermatitis is expected in December 2024.
- Out-Licensing: The company intends to out-license imsidolimab (anti-IL-36R) in 2024.
Risks and Contingencies:
- Capital Needs: The company has a history of operational losses and an accumulated deficit of $737.5 million. It will require additional capital to continue development and commercialization, which may not be available on acceptable terms.
- Development Risk: Product candidates are in clinical stages and may fail to demonstrate safety or efficacy, or face regulatory delays.
- Collaboration Dependence: Revenue is heavily dependent on the success of GSK's commercialization of Jemperli and the terms of the royalty monetization agreements.
- Non-Cash Revenue: All revenue recognized in the period was non-cash, derived from royalty monetization agreements where proceeds were received upfront and recorded as liabilities.
Key Facts for Investor Verification
- Revenue Quality: Verify the sustainability of revenue, as 100% of Q3 2024 revenue was non-cash (milestones and royalties monetized to third parties).
- Cash Burn vs. Runway: Confirm the 12-month runway estimate given the $68.7 million net cash used in operating activities over the first nine months of 2024.
- Royalty Liability: Monitor the $350.6 million liability for the sale of future royalties and the associated non-cash interest expense, which significantly impacts net loss.
- Clinical Data Readouts: Track the upcoming data readouts for ANB032 (Dec 2024) and rosnilimab (Feb 2025) as critical catalysts for valuation.
- Financing Terms: Review the terms of the August 2024 public offering and the amended Jemperli Royalty Monetization Agreement to understand future dilution and royalty obligations.